Xcout Intel
Talphera, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Talphera, Inc. among biotech companies — ranked by similarity to what Talphera, Inc. actually does, not by market-cap band.
Subscribe to see Talphera, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
Talphera, Inc. at a glance
Talphera, Inc. is a biotech company headquartered in San Mateo, United States. It is publicly listed (TLPH) with a market capitalisation of $64.4M. Xcout tracks 30 named people at Talphera, Inc., including Vincent J. Angotti (Chief Executive Officer & Director).
Talphera, Inc. leadership
- Vincent J. AngottiChief Executive Officer & Director
- Vince AngottiCEO
- Raffi Mark AsadorianChief Financial Officer
- Raffi AsadorianChief Financial Officer
- Shakil AslamChief Medical Officer
- Anil N. DasuChief Engineering Officer
24 more named people on record for Talphera, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Talphera, Inc. competitors
Ranked by semantic similarity — how close each company is to Talphera, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
Similar biotech company
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Similar biotech company
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
Biotechnology
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Biotechnology
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Similar biotech company
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.
Similar biotech company
Kyntra Bio, Inc. is a biopharmaceutical enterprise focused on the entire spectrum of therapeutic innovation, from discovering new compounds to developing and commercializing them. Leveraging profound insights into hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology, the company strives to engineer effective medicinal solutions for anemia, fibrotic conditions, and various forms of cancer. Founded by Thomas B. Neff on September 29, 1993, Kyntra Bio, Inc. maintains its corporate headquarters in San Francisco, California.
Similar biotech company
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Similar biotech company
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Similar biotech company
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
Similar biotech company
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
Similar biotech company
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Talphera, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Talphera, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →